Therapy-induced senescence as a component of tumor biology: Evidence from clinical cancer
T Saleh, S Bloukh, M Hasan, S Al Shboul - Biochimica et Biophysica Acta …, 2023 - Elsevier
Abstract Therapy-Induced Senescence (TIS) is an established response to anticancer
therapy in a variety of cancer models. Ample evidence has characterized the triggers …
therapy in a variety of cancer models. Ample evidence has characterized the triggers …
Cytoprotective, cytotoxic and cytostatic roles of autophagy in response to BET inhibitors
AM Elshazly, DA Gewirtz - International Journal of Molecular Sciences, 2023 - mdpi.com
The bromodomain and extra-terminal domain (BET) family inhibitors are small molecules
that target the dysregulated epigenetic readers, BRD2, BRD3, BRD4 and BRDT, at various …
that target the dysregulated epigenetic readers, BRD2, BRD3, BRD4 and BRDT, at various …
Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced …
JW Zhang, D Zhang, HS Yin, H Zhang, KQ Hong… - Gut …, 2023 - Taylor & Francis
Senescence frequently occurs in cancer cells in response to chemotherapy (called therapy-
induced senescence). Senescent cells can exert paracrine effects through the senescence …
induced senescence). Senescent cells can exert paracrine effects through the senescence …
The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant+ Palbociclib and suppresses proliferative recovery in ER-positive breast …
RM Finnegan, AM Elshazly, NH Patel… - Frontiers in …, 2023 - frontiersin.org
Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6
(CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her …
(CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her …
BRD4 inhibition as a strategy to prolong the response to standard of care in estrogen receptor-positive breast cancer
AM Elshazly, MM Sinanian, V Neely, E Chakraborty… - Cancers, 2023 - mdpi.com
Simple Summary The combination of CDK4/6 inhibitors+ fulvestrant or tamoxifen effectively
prolongs survival in patients with estrogen receptor-positive (ER+) breast cancer. However …
prolongs survival in patients with estrogen receptor-positive (ER+) breast cancer. However …
[HTML][HTML] Targeting cellular senescence in aging and age-related diseases: challenges, considerations, and the emerging role of senolytic and senomorphic therapies
L Zheng, S He, H Wang, J Li, Y Liu, S Liu - Aging and disease, 2024 - pmc.ncbi.nlm.nih.gov
Cellular senescence is characterized by the permanent arrest of cell proliferation and is a
response to endogenous and exogenous stress. The continuous accumulation of senescent …
response to endogenous and exogenous stress. The continuous accumulation of senescent …
Senolytic therapy: A potential approach for the elimination of oncogene-induced senescent HPV-positive cells
Senescence represents a unique cellular stress response characterized by a stable growth
arrest, macromolecular alterations, and wide spectrum changes in gene expression …
arrest, macromolecular alterations, and wide spectrum changes in gene expression …
The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
A Softah, MR Alotaibi, AR Alhoshani, T Saleh… - Biomedicines, 2023 - mdpi.com
Despite significant advances in the treatment of triple-negative breast cancer, this disease
continues to pose a clinical challenge, with many patients ultimately suffering from relapse …
continues to pose a clinical challenge, with many patients ultimately suffering from relapse …
Senotherapy, cancer, and aging
L Balducci, C Falandry, S Monfardini - Journal of Geriatric Oncology, 2024 - Elsevier
Introduction We aimed to highlight the effects of senotherapy on the prevention and
treatment of cancer in older individuals. The aim of senotherapy is to eliminate senescent …
treatment of cancer in older individuals. The aim of senotherapy is to eliminate senescent …
[HTML][HTML] Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinoma
Introduction Head and neck squamous cell carcinoma (HNSCC) is a common cancer with a
five-year survival rate around 60%, indicating a need for new treatments. BH3 mimetics are …
five-year survival rate around 60%, indicating a need for new treatments. BH3 mimetics are …